PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Sponsor: Pearl Therapeutics, Inc.
Listed as NCT01349816, this PHASE2 trial focuses on Chronic Obstructive Pulmonary Disease and remains completed. Sponsored by Pearl Therapeutics, Inc., it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
May 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — May 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pearl Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Brooklyn, United States , Charlotte, United States , Cincinnati, United States , Clearwater, United States , Colorado Springs, United States , Medford, United States , Minneapolis, United States , Pensacola, United States , Rancho Mirage, United States , Spartanburg, United States and 3 more locations